Literature DB >> 28944174

Hypertrophic obstructive cardiomyopathy-the Leipzig experience.

Jawad Khalil1, Michael Kuehl2, Pirose Davierwala1, Friedrich Wilhelm Mohr1, Martin Misfeld1.   

Abstract

BACKGROUND: Management of hypertrophic obstructive cardiomyopathy (HOCM) has evolved considerably over the last fifty years, and includes medical treatment as well as septal myectomy (SM) to relief symptoms caused by left ventricular outflow tract obstruction (LVOTO). We report the Leipzig Heart Center experience in the surgical management of patients with HOCM.
METHODS: We collected data from all patient treated surgically with a myectomy for LVOTO in patients with HOCM between 1997 and 2016. Patients with absent data were excluded from our analysis. All data were obtained from our surgical database and analyzed retrospectively.
RESULTS: We identified 115 patients who underwent surgical treatment for HOCM, where a male:female ratio of 1.1:1, a mean age of 60.8±14.6 years and a body mass index of 27.7±4.5 were observed. The most common symptom was dyspnea (n=102). Of all patients, 50% had New York Heart Association (NYHA) III class symptoms. Arterial hypertension was the most common comorbidity (n=80). Preoperative transthoracic echocardiography showed a mean ejection fraction (EF) of 65.9%±9.7%, median septal thickness of 21.1±5.3 mm, systolic anterior motion of the mitral valve (MV) in 61.7% of patients, and mean LVOT gradient of 70.1±45.2 mmHg. Surgery resulted in a mean decrease of the septal thickness by 15±3.7 mm and LVOT gradient by 9.7±8.5 mmHg. Isolated SM was carried out on 20 patients. Postoperatively, we were able to notice a significant improvement in NYHA classification, in which patients with NYHA III benefitted most from SM. Long-term follow-up data up to 11.3±0.7 years were available for 114 patients. During follow-up, 16 patients died, and one patient was lost to follow up.
CONCLUSIONS: Surgical treatment of LVOT in patients with HOCM is an effective intervention that improves cardiac function and quality of life (QoL) and is associated with a low operative risk.

Entities:  

Keywords:  Hypertrophic obstructive cardiomyopathy (HOCM); concomitant procedures; left ventricular outflow tract

Year:  2017        PMID: 28944174      PMCID: PMC5602203          DOI: 10.21037/acs.2017.07.09

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  26 in total

1.  IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS.

Authors:  E BRAUNWALD; C T LAMBREW; S D ROCKOFF; J ROSS; A G MORROW
Journal:  Circulation       Date:  1964-11       Impact factor: 29.690

2.  Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy.

Authors:  A G MORROW; E C BROCKENBROUGH
Journal:  Ann Surg       Date:  1961-08       Impact factor: 12.969

3.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

4.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy].

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Phillippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; Wiliam J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Kardiol Pol       Date:  2014       Impact factor: 3.108

5.  Operative treatment in idiopathic hypertrophic subaortic stenosis. Techniques, and the results of preoperative and postoperative clinical and hemodynamic assessments.

Authors:  A G Morrow; T J Fogarty; H Hannah; E Braunwald
Journal:  Circulation       Date:  1968-04       Impact factor: 29.690

6.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Steve R Ommen; Barry J Maron; Iacopo Olivotto; Martin S Maron; Franco Cecchi; Sandro Betocchi; Bernard J Gersh; Michael J Ackerman; Robert B McCully; Joseph A Dearani; Hartzell V Schaff; Gordon K Danielson; A Jamil Tajik; Rick A Nishimura
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

7.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy.

Authors:  Iacopo Olivotto; Martin S Maron; A Selcuk Adabag; Susan A Casey; Daniela Vargiu; Mark S Link; James E Udelson; Franco Cecchi; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

Review 8.  Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction.

Authors:  Mark V Sherrid; Farooq A Chaudhry; Daniel G Swistel
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

9.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

10.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy.

Authors:  X Jeanrenaud; J J Goy; L Kappenberger
Journal:  Lancet       Date:  1992-05-30       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.